Prime Medicine, Inc. Net Income
Prime Medicine, Inc. (PRME) reported Net Income of -$42.11 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- Prime Medicine, Inc. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$42.11M.
- Prime Medicine, Inc. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$49.12M.
- Prime Medicine, Inc. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$46.08M.
- Prime Medicine, Inc. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$50.58M.
- Prime Medicine, Inc. net income (loss) attributable to parent for fiscal 2025 was -$201.14M.
- Prime Medicine, Inc. net income (loss) attributable to parent for fiscal 2024 was -$195.88M.
- Prime Medicine, Inc. net income (loss) attributable to parent for fiscal 2023 was -$198.13M.
- Prime Medicine, Inc. net income (loss) attributable to parent for fiscal 2022 was -$121.82M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$42.11M 10-Q · filed 2026-08-06 | -$91.23M 10-Q · filed 2026-08-06 | -$137.31M derived: sum of 3 quarters · filed 2026-08-06 | -$187.89M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$49.12M 10-Q · filed 2026-08-06 | -$95.20M derived: sum of 2 quarters · filed 2026-08-06 | -$145.78M derived: sum of 3 quarters · filed 2026-08-06 | -$198.37M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$46.08M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$96.66M derived: sum of 2 quarters · filed 2026-03-03 | -$149.25M derived: sum of 3 quarters · filed 2026-08-06 | -$201.14M 10-K · filed 2026-03-03 |
| 2025-09-30 | -$50.58M 10-Q · filed 2025-11-07 | -$103.17M derived: sum of 2 quarters · filed 2026-08-06 | -$155.06M 10-Q · filed 2025-11-07 | -$197.34M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$52.59M 10-Q · filed 2026-08-06 | -$104.48M 10-Q · filed 2026-08-06 | -$146.76M derived: sum of 3 quarters · filed 2026-08-06 | -$199.28M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$51.89M 10-Q · filed 2026-08-06 | -$94.17M derived: sum of 2 quarters · filed 2026-08-06 | -$146.68M derived: sum of 3 quarters · filed 2026-08-06 | -$202.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2024-12-31 | -$42.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | -$94.79M derived: sum of 2 quarters · filed 2026-03-03 | -$150.12M derived: sum of 3 quarters · filed 2026-03-03 | -$195.88M 10-K · filed 2026-03-03 |
| 2024-09-30 | -$52.52M 10-Q · filed 2025-11-07 | -$107.84M derived: sum of 2 quarters · filed 2025-11-07 | -$153.61M 10-Q · filed 2025-11-07 | -$219.25M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-06-30 | -$55.33M 10-Q · filed 2025-11-07 | -$101.09M 10-Q · filed 2025-08-07 | -$166.73M derived: sum of 3 quarters · filed 2025-11-07 | -$217.44M derived: sum of 4 quarters · filed 2025-11-07 |
| 2024-03-31 | -$45.76M 10-Q · filed 2025-11-07 | -$111.40M derived: sum of 2 quarters · filed 2025-11-07 | -$162.11M derived: sum of 3 quarters · filed 2025-11-07 | -$204.50M derived: sum of 4 quarters · filed 2025-11-07 |
| 2023-12-31 | -$65.64M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-28 | -$116.35M derived: sum of 2 quarters · filed 2025-02-28 | -$158.74M derived: sum of 3 quarters · filed 2025-02-28 | -$198.13M 10-K · filed 2025-02-28 |
| 2023-09-30 | -$50.71M 10-Q · filed 2024-11-12 | -$93.09M derived: sum of 2 quarters · filed 2024-11-12 | -$132.49M 10-Q · filed 2024-11-12 | -$171.77M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$42.38M 10-Q · filed 2024-11-12 | -$81.78M 10-Q · filed 2024-08-08 | -$121.06M derived: sum of 3 quarters · filed 2024-11-12 | -$150.41M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-03-31 | -$39.40M 10-Q · filed 2024-11-12 | -$78.68M derived: sum of 2 quarters · filed 2024-11-12 | -$108.03M derived: sum of 3 quarters · filed 2024-11-12 | -$137.38M derived: sum of 4 quarters · filed 2024-11-12 |
| 2022-12-31 | -$39.28M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-01 | -$68.63M derived: sum of 2 quarters · filed 2024-03-01 | -$97.98M derived: sum of 3 quarters · filed 2024-03-01 | -$121.82M 10-K · filed 2024-03-01 |
| 2022-09-30 | -$29.35M 10-Q · filed 2023-11-03 | -$58.70M derived: sum of 2 quarters · filed 2023-11-03 | -$82.54M 10-Q · filed 2023-11-03 | -$145.45M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-06-30 | -$29.35M 10-Q · filed 2023-11-03 | -$53.19M 10-Q · filed 2023-08-07 | -$116.10M derived: sum of 3 quarters · filed 2023-11-03 | -$132.51M derived: sum of 4 quarters · filed 2023-11-03 |
| 2022-03-31 | -$23.84M 10-Q · filed 2023-11-03 | -$86.75M derived: sum of 2 quarters · filed 2023-11-03 | -$103.16M derived: sum of 3 quarters · filed 2023-11-03 | -$102.55M derived: sum of 4 quarters · filed 2023-11-03 |
| 2021-12-31 | -$62.91M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-09 | -$79.32M derived: sum of 2 quarters · filed 2023-03-09 | -$78.71M derived: sum of 3 quarters · filed 2023-03-09 | -$165.37M 10-K · filed 2023-03-09 |
| 2021-09-30 | -$16.41M 10-Q · filed 2022-11-14 | -$15.80M derived: sum of 2 quarters · filed 2022-11-14 | -$102.46M 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $616.00K 10-Q · filed 2022-11-14 | -$86.04M derived: sum of 2 quarters · filed 2022-11-14 | ||
| 2021-03-31 | -$86.66M 10-Q · filed 2022-11-14 | |||
| 2020-12-31 | -$3.41M 10-K · filed 2023-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B |